Cancer Research Technology
Log in Register
Menu
Search
Monoclonal Antibodies

Anti-FN-EDB [4A10.1] monoclonal antibody

Invented at University of Tartu
  • Datasheet
  • Inventor Info
Print

Info

Image thumbnail for Anti-FN-EDB [4A10.1] monoclonal antibody
Add an image
Linasamy et al., 2019. https://doi.org/10.1016/j.biomaterials.2019.119373 Antibody clones not declared.
Add an image
Image thumbnail for Anti-FN-EDB [4A10.1] monoclonal antibody
Catalogue Number 160458
Applications ELISA IHC
Antigen/Gene or Protein Targets Extra domain B of fibronectin, EDB-FN
Reactivity Human
Relevance Oncofetal fibronectin (FN-EDB) and tenascin-C C domain (TNC-C) are nearly absent in extracellular matrix of normal adult tissues but upregulated in malignant tissues. Both FN-EDB and TNC-C are developed as targets of antibody-based therapies.

This series of antibodies has been validated in vitro against glioblastoma (GBM) and prostate carcinoma xenografts, and to non-malignant angiogenic neovessels induced by VEGF-overexpression.

Please see our related anti-FN-EDB antibodies from University of Tartu.
Research Area Cancer

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Lingasamy et al. 2019. Biomaterials. 219:119373. PMID: 31374479.

View  

Add a reference

References: 1 entry

Lingasamy et al. 2019. Biomaterials. 219:119373. PMID: 31374479.

View  

Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor

Invented at

University of Tartu
University of Tartu

27 reagents listed on Ximbio